文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

阴部神经阻滞作为宫颈近距离放疗多模式镇痛组成部分的有效性与安全性

Efficacy and safety of the pudendal nerve block as a component of multimodal analgesia for cervical brachytherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-06-27

该回顾性研究纳入78例接受149次宫颈近距离放疗的患者,比较引入阴部神经阻滞(PNB)前后两个时期的疼痛评分、镇痛可接受性、阿片类药物需求及不良事件。PNB组中位疼痛评分更低(1 vs 2.5;p=0.003),不可接受疼痛发作更少(33% vs 63%;p<0.001),PCA阿片需求减少(p<0.001),且低血压、呼吸抑制或恶心发生率无差异。作者推荐在宫颈近距离放疗的多模式镇痛方案中常规使用PNB。

要点

  • PNB组中位疼痛评分显著低于对照组(1 vs 2.5;p=0.003)。
  • PNB组不可接受疼痛发作比例更低(33% vs 63%;p<0.001)。
  • PNB与PCA阿片需求减少相关(p<0.001),不良事件无差异。

核心结论

  • PNB是全麻加静脉PCA用于宫颈近距离放疗的有效且安全的辅助镇痛方式,可改善疼痛并减少阿片需求。
  • 作者主张在多模式镇痛方案中常规使用PNB。

研究设计与样本

  • 回顾性研究,纳入78例接受149次宫颈近距离放疗的宫颈恶性肿瘤患者,比较引入PNB前后两个时期。
  • PNB在全身麻醉下使用1%罗哌卡因行双侧阻滞,术后使用静脉患者自控镇痛(PCA)。
  • 近距离放疗按EMBRACE-2方案行腔内和/或组织间插植治疗。

主要发现

  • 149次近距离放疗中95次(64%)使用了PNB。
  • 两个队列中48%的病例需要插植针,人口学特征无显著差异。
  • PNB组中位疼痛评分更低(1 vs 2.5;p=0.003)。
  • PNB组不可接受疼痛(记录评分≥4的比例<20%)发作更少(33% vs 63%;p<0.001)。
  • PNB与PCA阿片需求减少相关(p<0.001),两组低血压、呼吸抑制或恶心发生率无差异。

关键数值与推荐

  • 疼痛评分采用11点数字评定量表,不可接受疼痛定义为记录评分中≥4分的比例<20%。
  • PNB组不可接受疼痛发作比例为33%,对照组为63%(p<0.001)。
  • PNB组中位疼痛评分为1,对照组为2.5(p=0.003)。

临床怎么用

  • 宫颈近距离放疗可在全麻加静脉PCA基础上联合双侧PNB(1%罗哌卡因)作为多模式镇痛组成部分。
  • PNB有助于降低疼痛评分、减少不可接受疼痛发作及PCA阿片需求,且不增加低血压、呼吸抑制或恶心风险。

局限性

  • 回顾性研究设计,比较两个时间时期,可能存在时间偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Whilst an essential component of curative management, cervical brachytherapy is associated with considerable pain and discomfort, with analgesic protocols varying between institutions. We present the first series on adjunctive pudendal nerve block (PNB) in addition to routine anaesthesia. METHODS: Retrospective review of patients receiving brachytherapy for cervical malignancies across two time periods, correlating to the institutional introduction of PNB. Technically, bilateral PNB was performed using 1 % ropivacaine under general anaesthesia and intravenous patient-controlled analgesia (PCA) was used post-operatively. Median pain scores (11-point numeric rating scale), acceptability of pain (<20 % of recorded scores ≥ 4), opioid requirement and adverse events are reported. Intracavitary with or without interstitial brachytherapy was performed as per EMBRACE-2 protocol. RESULTS: 78 patients receiving 149 brachytherapy episodes were included, of which 95 episodes (64%) utilised PNB. 48% of cases required interstitial needles in both cohorts, with no significant differences in demographics.Median pain scores were lower in the PNB cohort (1 vs. 2.5; p = 0.003). PNB was associated with less episodes of unacceptable pain, as defined above (33 % vs. 63 %; p < 0.001). This benefit was sustained on binomial logistic regression, including such factors as number of interstitial needles, baseline opioid use and applicator model choice.PNB use was also associated with reduced opioid requirement via PCA (p < 0.001) and there were no differences in the incidence of hypotension, respiratory depression or nausea between cohorts. CONCLUSIONS: PNB is an effective and safe adjunct to general anaesthesia and intravenous PCA for cervical brachytherapy, with improved pain and reduced opioid requirements. We advocate for routine use of PNB in addition to multimodal analgesic regimens.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Knox MC, Thiruthaneeswaran N, Zhong G, et al. Efficacy and safety of the pudendal nerve block as a component of multimodal analgesia for cervical brachytherapy. Clin Transl Radiat Oncol. 2025. PMID: 40677621. doi:10.1016/j.ctro.2025.101001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。